ABCL635
Phase 1/2
First-in-class antibody medicine for the non-hormonal treatment of vasomotor symptoms, listed at Phase 1/2 on the company pipeline.
Learn more Source
AbCellera Biologics
Biotechnology & Life SciencesAINasdaq: ABCLVancouver, BC
Vancouver-based clinical-stage biotechnology company that uses its in-house antibody discovery and characterization platform to find and develop antibody-based medicines.
Canadian innovation builds a brighter tomorrow.
About
Source: abcellera.comAbCellera describes itself as a place that exists to push the limits of science and technology, focused on delivering breakthrough medicines that alleviate suffering, extend lives and improve health. Founded as an academic spinout and headquartered at 150 W 4th Ave in Vancouver, it runs a high-throughput microfluidic single-cell platform for antibody discovery with integrated capabilities from target identification through clinical manufacturing.
Reported positive topline Phase 2 results for ABCL635 in moderate-to-severe menopausal vasomotor symptoms in August 2026. investors.abcellera.com
Priced an oversubscribed offering of 17,435,897 common shares at $9.75 in August 2026, for roughly $200M in gross proceeds. investors.abcellera.com
Signed a research collaboration with Jazz Pharmaceuticals in June 2026: $56M upfront for the first two programs, plus up to $792M per program in milestones. investors.abcellera.com
Its FY2025 annual report states 562 full-time employees across Canada, Australia and the United States, and about $1 billion invested in its platform since 2012. sec.gov
Its FY2021 Form 10-K states the technology stack integrates microfluidics, single-cell analysis, high-throughput genomics, machine learning and hyper-scale data science. sec.gov
Its FY2020 Form 10-K describes Celium, a computational engine for mining campaign data, and AI-based machine vision tools that process single-cell screening images in real time. sec.gov
Products & Services
Company site: abcellera.comProducts AbCellera Biologics publishes on its own site. Each card links to the page it was taken from.
ABCL575
Phase 1
Investigational monoclonal antibody for moderate-to-severe atopic dermatitis, listed at Phase 1.
Learn more SourceABCL688
IND-enabling
Programme targeting a multipass complex membrane protein in autoimmunity, listed at IND-enabling stage.
Learn moreABCL386
Discovery / IND-enabling
Potential antibody medicine for an undisclosed oncology indication, listed at discovery to IND-enabling stage.
Learn morePartnerships
Publicly announced partnerships.
Jazz Pharmaceuticals
Research collaboration announced June 2026: $56M upfront for the first two programs plus up to $792M per program in milestones, on T-cell engaging multispecific antibodies.
People
Sourced from the company's own pages or announcements.
Carl Hansen
Chairman, Chief Executive Officer & President
Veronique Lecault
Director & Chief Technology Officer
Andrew Booth
Chief Financial Officer
Sarah Noonberg
Chief Medical Officer
Technology Focus
Company site: abcellera.comTerms the company uses about its own work.
Antibody discoveryMicrofluidic single-cell analysisHigh-throughput screeningMonoclonal antibodiesT-cell engaging multispecificsClinical manufacturing
Similar Companies
Other companies in Biotechnology & Life Sciences.
